Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7398MR)

This product GTTS-WQ7398MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7398MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5682MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ15346MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ8207MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ10804MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ4597MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ14493MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ3797MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ14315MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG7414
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW